Analysts at Redburn Atlantic assumed coverage on shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) in a note issued to investors on Tuesday, Briefing.com reports. The firm set a “buy” rating on the stock.
GMAB has been the topic of several other research reports. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Friday, September 20th. BTIG Research lifted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.
Check Out Our Latest Stock Analysis on GMAB
Genmab A/S Price Performance
Genmab A/S (NASDAQ:GMAB – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The company had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. As a group, equities analysts expect that Genmab A/S will post 1.27 EPS for the current year.
Hedge Funds Weigh In On Genmab A/S
Several hedge funds and other institutional investors have recently made changes to their positions in GMAB. Capital International Investors grew its stake in Genmab A/S by 7.8% during the 1st quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after acquiring an additional 315,355 shares in the last quarter. Harding Loevner LP grew its position in shares of Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after purchasing an additional 103,859 shares during the last quarter. DDD Partners LLC purchased a new position in Genmab A/S during the second quarter worth approximately $8,860,000. Finally, Cubist Systematic Strategies LLC boosted its stake in Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after buying an additional 145,689 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- What Is WallStreetBets and What Stocks Are They Targeting?
- Exxon Mobil Stock on the Move: Why a 30% Surge Is Just the Start
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Levi’s Revenue Dips, But Record Margins Might Stitch Things Up
- Find and Profitably Trade Stocks at 52-Week Lows
- Top 3 Growth Stocks Poised for a Strong Q4 2024 Rally
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.